클로자핀 유발성 빈혈 및 혈소판 증가증 증례
A Case of Clozapine-Induced Anemia and Thrombocytosis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Clozapine is a well-known antipsychotic which causes hematologic adverse effects, specifically neutropenia and agranulocytosis (1–3% of patients). However, reports on blood dyscrasias like anemia and thrombocytosis after clozapine treatment are extremely rare. In some cases re-challenge of clozapine could lead to hematopoietic abnormality related to thrombocytopenia or thrombocytosis, which may be a result of an immune reaction. This case report suggests that clinicians should monitor platelet count after re-treatment with clozapine.
Abstract
Clozapine is a well-known antipsychotic which causes hematologic adverse effects, specifically neutropenia and agranulocytosis (1–3% of patients). However, reports on blood dyscrasias like anemia and thrombocytosis after clozapine treatment are extremely rare. In some cases re-challenge of clozapine could lead to hematopoietic abnormality related to thrombocytopenia or thrombocytosis, which may be a result of an immune reaction. This case report suggests that clinicians should monitor platelet count after re-treatment with clozapine.
참고문헌 (29)
- Baldessarini RJ, "A novel antipsychotic agent", N Engl J Med, 324, pp.746~754 (1991)
- Lieberman JA, "The effects of clozapine on tardive dyskinesia", Br J Psychiatry, 158, pp.503~510 (1991)
- Meltzer HY, "Clozapine treatment for suicidality in schizophrenia: international Suicide Prevention Trial (InterSePT)", Arch Gen Psychiatry, 60, pp.82~91 (2003)
- Kant R, "The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder", J Child Adolesc Psychopharmacol, 14, pp.57~63 (2004)
- Weiss E, "Off-label use of antipsychotic drugs", J Clin Psychopharmacol, 20, pp.695~698 (2000)
- The Parkinson Study Group, "Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease", N Engl J Med, 340, pp.757~763 (1999)
- Hummer M, "Clozapine-induced transient white blood count disorders", J Clin Psychiatry, 55, pp.429~432 (1994)
- Buchanan RW, "Clozapine: efficacy and safety", Schizophr Bull, 21, pp.579~591 (1995)
- Durst R, "Platelet dysfunction associated with clozapine therapy", South Med J, 86, pp.1170~1172 (1993)
- Young CR, "Management of the adverse effects of clozapine", Schizophr Bull, 24, pp.381~390 (1998)
- Gareri P, "The safety of clozapine in the elderly", Expert Opin Drug Saf, 7, pp.525~538 (2008)
- Savithasri Eranti V, "Maked thrombocyte count variations without agranuloctosis due to clozapine", Indian J Psychiatry, 40, pp.300~302 (1998)
- Papadakis M, "Current medical diagnosis &treatment 2014" (2014), McGraw-Hill Education
- Harrison CN, "Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia", N Engl J Med, 353, pp.33~45 (2005)
- Thorup M, "Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors", Acta Psychiatr Scand, 55, pp.123~126 (1977)
- Paciullo CA, "Evaluating the association between clozapine and venous thromboembolism", Am J Health Syst Pharm, 65, pp.1825~1829 (2008)
- Hampson ME, "Clozapine-induced thrombocytosis", Br J Psychiatry, 176, pp.400~ (2000)
- Marlowe K, "Thrombocytosis due to clozapine treatment: working towards an early marker for clozapine-induced agranulocytosis", Br J Psychiatry, 177, pp.372~373 (2000)
- Kim YS, "Clinical use of clozapine: 89questions and answers.", pp.143~144 (2013), SNU press
- Alvir JM, "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States", N Engl J Med, 329, pp.162~167 (1993)
- Arranz M, "Association between clozapine response and allelic variation in 5-HT2A receptor gene", Lancet, 346, pp.281~282 (1995)
- Dietrich-Muszalska A, "The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation", World J Biol Psychiatry, 11(2 Pt 2), pp.268~275 (2010)
- Schedel A, "The effect of psychoactive drugs on in vitro platelet function", Transfus Med Hemother, 37, pp.293~298 (2010)
- Hägg S, "Association of venous thromboembolism and clozapine", Lancet, 355, pp.1155~1156 (2000)
- Iqbal MM, "Clozapine: a clinical review of adverse effects and management", Ann Clin Psychiatry, 15, pp.33~48 (2003)
- Arranz MJ, "Pharmacogenetic prediction of clozapine response", Lancet, 355, pp.1615~1616 (2000)
- Arranz MJ, "Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research", Mol Psychiatry, 12, pp.707~747 (2007)
- 김희철, "Clozapine에 의한 백혈구 및 호산구 증다증 1례", 생물치료정신의학, 3(2), pp.265~270 (1997), 대한생물치료정신의학회
- 조만제, "한국에서 11년간 Clozapine 투여에 의한 무과립구증과 호중구감소증", 생물치료정신의학, 10(2), pp.184~191 (2004), 대한생물치료정신의학회